본문 바로가기
KERD
논문KCI 등재

Autologous cell-free serum preparations in the management of knee osteoarthritis: what is the current clinical evidence?

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

초록

Background: There is paucity in the current literature regarding clinical outcomes of autologous cell-free serum preparations. The objective of this paper is to collate the clinical evidence and review the results of intraarticular injections of autologous cell-free serum preparations in the management of knee osteoarthritis (OA). Methods: A comprehensive English literature search was undertaken using the healthcare database website (https://hdas.nice.org.uk/). The PubMed, Medline, CINAHL, Embase and the Cochrane library databases were searched to identify all studies of autologous protein solution/autologous conditioned serum (ACS/APS) in the management of knee OA. We evaluated the reported clinical outcomes with respect to pain, function, morbidity, adverse effects and complications. Results: Fifteen relevant articles were identified in the current literature. Outcomes following injection of ACS/APS have been reported in patients with age range (34–87 years) and unilateral or bilateral knee OA. Seven studies reported improvement in visual analog scale (VAS) whereas the Western Ontario and McMaster Universities osteoarthritis instrument (WOMAC) score improved in nine studies. Considerable variation was noted in the injection technique and duration of post-procedure assessment with only one study reporting long-term follow-up beyond 24 months. Joint swelling and injection-site pain were reported to be the most common complications; only one study reported a case of septic arthritis. However, no evidence is available to clearly identify factors that may predict the outcomes following this procedure. Conclusion: Current data from the clinical studies would suggest that the intraarticular administration of autologous cell-free serum preparations, such as ACS/APS, in patients with knee OA may improve pain and function, with limited morbidity. High-quality clinical trials with stratified patient cohorts, longer follow-up duration and robust reporting of outcome measures are essential to improve the understanding of the indications and clinical effectiveness of these novel products.

Abstract

Background: There is paucity in the current literature regarding clinical outcomes of autologous cell-free serum preparations. The objective of this paper is to collate the clinical evidence and review the results of intraarticular injections of autologous cell-free serum preparations in the management of knee osteoarthritis (OA). Methods: A comprehensive English literature search was undertaken using the healthcare database website (https://hdas.nice.org.uk/). The PubMed, Medline, CINAHL, Embase and the Cochrane library databases were searched to identify all studies of autologous protein solution/autologous conditioned serum (ACS/APS) in the management of knee OA. We evaluated the reported clinical outcomes with respect to pain, function, morbidity, adverse effects and complications. Results: Fifteen relevant articles were identified in the current literature. Outcomes following injection of ACS/APS have been reported in patients with age range (34–87 years) and unilateral or bilateral knee OA. Seven studies reported improvement in visual analog scale (VAS) whereas the Western Ontario and McMaster Universities osteoarthritis instrument (WOMAC) score improved in nine studies. Considerable variation was noted in the injection technique and duration of post-procedure assessment with only one study reporting long-term follow-up beyond 24 months. Joint swelling and injection-site pain were reported to be the most common complications; only one study reported a case of septic arthritis. However, no evidence is available to clearly identify factors that may predict the outcomes following this procedure. Conclusion: Current data from the clinical studies would suggest that the intraarticular administration of autologous cell-free serum preparations, such as ACS/APS, in patients with knee OA may improve pain and function, with limited morbidity. High-quality clinical trials with stratified patient cohorts, longer follow-up duration and robust reporting of outcome measures are essential to improve the understanding of the indications and clinical effectiveness of these novel products.

참고문헌 (69)

  1. Kiadaliri AA, "High and rising burden of hip and knee osteoarthritis in the Nordic region, 1990–2015 : findings from the Global Burden of Disease Study 2015", Acta Orthop, 89(2), pp.177~183 (2018)
  2. Liu Q, "Knee symptomatic osteoarthritis, walking disability, NSAIDs use and all-cause mortality : population-based Wuchuan osteoarthritis study", Sci Rep, 7(1), pp.3309~ (2017)
  3. Yates AJJ, "AAOS appropriate use criteria: optimizing the non-arthroplasty management of osteoarthritis of the knee", J Am Acad Orthop Surg, 22(4), pp.261~267 (2014)
  4. Abbott J, "Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee : 2-year results of the MOA randomised controlled trial", Osteoarthr Cartil, 27(3), pp.424~434 (2019)
  5. Messier SP, "Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better?", Arthritis Care Res, 70(11), pp.1569~1575 (2018)
  6. Hee-Soo Kyung, "High Tibial Osteotomy for Medial Knee Osteoarthritis", Knee Surgery and Related Research, 28(4), pp.253~254 (2016), 대한슬관절학회
  7. Passias PG, "Total knee arthroplasty in patients of advanced age: a look at outcomes and complications", J Knee Surg, 33(1), pp.1~7 (2018)
  8. Healy WL, "Complications of total knee arthroplasty : standardized list and definitions of the Knee Society", Clin Orthop Relat Res, 471(1), pp.215~220 (2013)
  9. Barker KL, "Knee arthroplasty patients predicted versus actual recovery: what are their expectations about time of recovery after surgery and how long before they can do the tasks they want to do?", Arch Phys Med Rehabil, 99(11), pp.2230~2237 (2018)
  10. Koenig KM, "The use of hyaluronic acid and corticosteroid injections among Medicare patients with knee osteoarthritis", J Arthroplast, 31(2), pp.351~355 (2016)
  11. Syed HM, "Bupivacaine and triamcinolone may be toxic to human chondrocytes : a pilot study", Clin Orthop Relat Res, 469(10), pp.2941~2947 (2011)
  12. Wehling P, "Effectiveness of intraarticular therapies in osteoarthritis : a literature review", Ther Adv Musculoskel Dis, 9(8), pp.183~196 (2017)
  13. Altman R, "Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis : a systematic review", Semin Arthritis Rheum, 48(2), pp.168~175 (2018)
  14. Jevsevar DS, "Treatment of osteoarthritis of the knee, 2nd edition : evidence-based guideline", J Am Acad Orthop Surg, 21(9), pp.571~576 (2013)
  15. Wu Y-T, "Effects of platelet-rich plasma on pain and muscle strength in patients with knee osteoarthritis", Am J Phys Med Rehabil, 97(4), pp.248~254 (2018)
  16. Iijima H, "Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis : a meta-analysis toward the establishment of effective regenerative rehabilitation", NPJ Regen Med, 3(1), pp.1~13 (2018)
  17. Vitale ND, "Innovative regenerative medicine in the management of knee OA : the role of autologous protein solution", J Clin Orthop Trauma, 10(1), pp.49~52 (2019)
  18. O'Shaughnessey K, "Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors", J Orthop Res, 32(10), pp.1349~1355 (2014)
  19. Frisbie DD, "Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis", Am J Vet Res, 68(3), pp.290~296 (2007)
  20. Hix JK, "An autologous anti-inflammatory protein solution yielded a favorable safety profile and significant pain relief in an open-label pilot study of patients with osteoarthritis", Biores Open Access, 6(1), pp.151~158 (2017)
  21. van Drumpt RAM, "Safety and treatment effectiveness of a single autologous protein solution injection in patients with knee osteoarthritis", Biores Open Access, 5(1), pp.261~268 (2016)
  22. Kon EE, "Clinical outcomes of knee osteoarthritis treated with an autologous protein solution injection : a 1-year pilot double-blinded randomized controlled trial", Am J Sports Med, 46(1), pp.171~180 (2018)
  23. Zarringam DB, "Long-term effect of injection treatment for osteoarthritis in the knee by Orthokin autologous conditioned serum", Cartilage, 9(2), pp.140~145 (2018)
  24. Tassara MDP, "Autologous conditioned serum(ACS)for intraarticular treatment in osteoarthritis : retrospective report of 28 cases", Transfus Apher Sci, 57(4), pp.573~577 (2018)
  25. Moser C, "Treatment of knee osteoarthritis with autologous conditioned serum (ACS): a prospective, randomized, placebocontrolled, patient- and observer-blind, parallel-design trial. Therapeutic study, level I (randomized controlled trial-RCT, ISRCTN: 71311752)", J Bone Joint Surg Proc, 91(B(Suppl_I)), pp.157~ (2009)
  26. Rutgers M, "Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection", Arthritis Res Ther, 12(3), pp.R114~ (2010)
  27. Bertone AL, "Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses", Am J Vet Res, 75(2), pp.141~151 (2014)
  28. "Multidisciplinary European Database"[URL]
  29. "OpenDOAR: Directory of Open Access Repositories"[URL]
  30. Hang DW, "Efficacy study of the treatment of osteoarthritis-induced knee pain with autologous conditioned serum: A comparative, prospective and randomized study", Osteoporos Int, 26(1), pp.56~ (2015)
  31. Barreto A, "A new treatment for knee osteoarthritis : clinical evidence for the efficacy of Arthrokinex™ autologous conditioned serum", J Orthop, 14(1), pp.4~9 (2017)
  32. Barreto A, "A new treatment for knee osteoarthritis : clinical evidence for the efficacy of ArthrokinexTM autologous conditioned serum", J Orthop, 14(1), pp.4~9 (2017)
  33. Hang D, "Treatment of osteoarthritis knee with autologous conditioned serum : Comparative, prospective study", Osteoporos Int, 28(1), pp.160~ (2017)
  34. Shirokova KN, "Comparison of clinical efficacy of platelet-rich plasma and autologous conditioned serum treatment in patients with osteoarthritis of the knee", Osteoarthritis Cartilage, 25(1), pp.S438~ (2017)
  35. García-Escudero JB, "Treatment of osteoarthritis of the knee with a combination of autologous conditioned serum and physiotherapy: a two-year observational study", PLoS One, 10(12), pp.e0145551~ (2015)
  36. Rutgers M, "Osteoarthritis treatment using autologous conditioned serum after placebo", Acta Orthop, 86(1), pp.114~118 (2015)
  37. Motaal FE, "Low-dose intra-articular autologous conditioned serum in treatment of primary knee osteoarthritis", Egypt Rheumatol Rehabil, 41(3), pp.98~ (2014)
  38. Baltzer AWA, "Autologous conditioned serum(Orthokine)is an effective treatment for knee osteoarthritis", Osteoarthr Cartil, 17(2), pp.152~160 (2009)
  39. Yang KR, "Autologous interleukin-1receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial", Osteoarthr Cartil, 16(4), pp.498~505 (2008)
  40. Richards MM, "Intraarticular treatment of knee osteoarthritis : from anti-inflammatories to products of regenerative medicine", Phys Sportsmed, 44(2), pp.101~108 (2016)
  41. Evans CH, "Autologous conditioned serum", Phys Med Rehabil Clin, 27(4), pp.893~908 (2016)
  42. "nSTRIDE APS versus hyaluronic acid for knee osteoarthritis"[URL]
  43. Biomet Z, "nSTRIDE® autologous protein solution kit" (2018), ZimmerBiomet
  44. Wehling P, "Autologous conditioned serum in the treatment of orthopedic diseases", BioDrugs, 21(5), pp.323~332 (2007)
  45. Wehling P, "How does surgery compare with advanced intra-articular therapies in knee osteoarthritis : current thoughts", Ther Adv Musculoskelet Dis, 8(3), pp.72~85 (2016)
  46. Woodell-May J, "Autologous protein solution inhibits MMP-13 production by IL-1β and TNFαstimulated human articular chondrocytes", J Orthop Res, 29(9), pp.1320~1326 (2011)
  47. Linardi RL, "The Effect of Autologous Protein Solution on the Inflammatory Cascade in Stimulated Equine Chondrocytes", Front Vet Sci, 6, pp.64~ (2019)
  48. Fox BA, "Treatment of knee osteoarthritis with Orthokine-derived autologous conditioned serum", Expert Rev Clin Immunol, 6(3), pp.335~345 (2010)
  49. Barreto A, "A method to induce interleukin-1 receptor antagonist protein from autologous whole blood", Cytokine, 81(1), pp.137~141 (2016)
  50. Chevalier X, "Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis : a multicenter study", J Rheumatol, 32(7), pp.1317~1323 (2005)
  51. Ulrich-Vinther M, "Articular cartilage biology", J Am Acad Orthop Surg, 11(6), pp.421~430 (2003)
  52. Frizziero A, "Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders", Br Med Bull, 105(1), pp.169~184 (2012)
  53. Frisbie DD, "Autologous-conditioned serum : evidence for use in the knee", J Knee Surg, 28(1), pp.63~66 (2015)
  54. "APSS-33-00: a multicenter, pilot study of Autologous Protein Solution (APS)in Knee Osteoarthritis (OA) (PROGRESS II)"[URL]
  55. Collins JA, "Bone marrow edema : chronic bone marrow lesions of the knee and the association with osteoarthritis", Bulletin Hosp Jt Dis, 74(1), pp.24~ (2016)
  56. Roemer FW, "Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally : the MOST study", Osteoarthr Cartil, 18(1), pp.47~53 (2010)
  57. Crnogaca K, "Elevated CRP level could herald less efficient autologous conditioned serum(ACS)treatment", Med Hypotheses, 86, pp.135~137 (2016)
  58. Zheng H, "Body mass index and risk of knee osteoarthritis:systematic review and meta-analysis of prospective studies", BMJ Open, 5(12), pp.e007568~ (2015)
  59. Weiss E, "Knee osteoarthritis, body mass index and pain : data from the Osteoarthritis Initiative", Rheumatology, 53(11), pp.2095~2099 (2014)
  60. Felson DT, "Valgus malalignment is a risk factor for lateral knee osteoarthritis incidence and progression : findings from the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative", Arthritis Rheum, 65(2), pp.355~362 (2013)
  61. Hayashi D, "Knee malalignment is associated with an increased risk for incident and enlarging bone marrow lesions in the more loaded compartments : the MOST study", Osteoarthr Cartil, 20(11), pp.1227~1233 (2012)
  62. Baltzer A, "Intraartikuläre Therapie der Gonarthrose mit autologem Interleukin-1Rezeptor Antagonisten(IL-1Ra)", Deutsche Zeitschrift für Sportmedizin, 54(6), pp.209~211 (2003)
  63. "Orthogen Laboratory Services: Doctor’s Questions and our Answers"[URL]
  64. "Zimmer Biomet: nSTRIDE Price. Email correspondence"[URL]
  65. "Monthly Index of Medical Specialities: Synvisc"[URL]
  66. "British National Formulary: Triamcinolone Acetonide"[URL]
  67. "Platelet Rich Plasma (PRP) Injections – Outpatient Pricing"[URL]
  68. "Knee Autologous Stem Cell Therapy (W3110)"[URL]

관련 논문AI추천

Intra-Articular Injection of Bone Marrow-Derived Mesenchymal Stem Cells Leading to Better Clinical Outcomes without Difference in MRI Outcomes from Baseline in Patients with Knee Osteoarthritis김희선, 이선희, Jung Ro Yoon, Young­Soo Shin대한슬관절학회 · Knee Surgery and Related Research2018 · 제30권 제3호The Effects of Intra-Articular Platelet-Rich Plasma Injection According to the Severity of Collagenase-Induced Knee Osteoarthritis in a Rabbit Model권동락, 박기영, Sung-uk Lee대한재활의학회 · Annals of Rehabilitation Medicine2012 · 제36권 제4호Efficacy and Safety of Intra-articular Injections of Hyaluronic Acid Combined With Polydeoxyribonucleotide in the Treatment of Knee OsteoarthritisJong Moon Kim, Jungin Kim, Jung Joong Kang, Seihee Yoon, Seunghun Park대한재활의학회 · Annals of Rehabilitation Medicine2019 · 제43권 제2호The use of platelet-rich plasma in management of musculoskeletal pain: a narrative reviewAung Chan Thu영남대학교 의과대학 · Journal of Yeungnam Medical Science2022 · 제39권 제3호Platelet-Rich Plasma Therapy for Knee Joint Problems: Review of the Literature, Current Practice and Legal Perspectives in Korea송상준, 하철원, Seung Beom Han, Tae Jin Kim, Yong-Geun Park대한슬관절학회 · Knee Surgery and Related Research2012 · 제24권 제2호Current perspectives in stem cell therapies for osteoarthritis of the knee김기범, 손욱진영남대학교 의과대학 · Journal of Yeungnam Medical Science2020 · 제37권 제3호

이 간행물의 다른 논문 (63건)